RenovoRx, Inc. (RNXT) Stock Analysis & Investment Frameworks
RenovoRx, Inc. (RNXT) stock analysis on Invetso. Review RenovoRx, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
RenovoRx, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
RenovoRx, Inc. Key Financial Metrics
- Market Cap: $55.51M
- Revenue: $1.12M
- ROE: -145.63%
- ROIC: -139.74%
- Dividend Yield: N/A
About RenovoRx, Inc.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RenovoRx, Inc. Investment Frameworks
Invetso analyzes RenovoRx, Inc. (RNXT) across the following frameworks:
- RenovoRx, Inc. 10Y Growth Potential
- RenovoRx, Inc. Scenario Analysis
- RenovoRx, Inc. Risks & Opportunities
- RenovoRx, Inc. Economic Moat
- RenovoRx, Inc. Business Model
- RenovoRx, Inc. Management
- RenovoRx, Inc. SWOT Analysis
- RenovoRx, Inc. Porter's 5 Forces
- RenovoRx, Inc. PESTLE Analysis
- RenovoRx, Inc. ESG Analysis